Alzamend Neuro, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALZN Nasdaq 2830 www.alzamend.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alzamend Neuro, Inc.

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital - Apr 7th, 2026 6:00 am
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions - Mar 26th, 2026 6:00 am
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital - Mar 16th, 2026 6:00 am
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Jan 26th, 2026 7:40 am
EMBC Q4 Preview: Product Momentum and Strategy Gains to Support Growth? - Nov 20th, 2025 5:50 am
Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital - Nov 19th, 2025 6:00 am
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants - Nov 19th, 2025 5:30 am
Alzamend Neuro to Present at the 2025 Military Health System Research Symposium - Jul 28th, 2025 6:00 am
Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs - Jul 23rd, 2025 6:00 am
Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule - Jun 16th, 2025 6:00 am